You may find the transcript here and analytics here.
Some of the questions and responses during the chat are below:
T1: Pls comment on the study at SGO you found of most note. Was it OC FANG vaccine/ GOG 213 studies/ other?
T1: Tho study was smalll, FANG vaccine for #ovariancancer is very exciting #immunotherapy has promise - esp in maintanence setting #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015
T1 @btrfly12 #gyncsm fang vaccine was for consolidation, i.e. after patients had had a complete response to front line chemotherapy
— Stephanie Blank (@StephanieVBlank) April 9, 2015
T1: GOG213:Avastin 4 platinum-sens #ovariancancer had similar results 2 prior studies - PFS benefit, Near OS benefit - but not quite #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015
#gyncsm I was encouraged by the biomarkers found from the ARIEL2 study #sgo2015
— Stephanie Blank (@StephanieVBlank) April 9, 2015
Impact of @theNCI Comprehensive Cancer Centers on #OvarianCancer Treatment and Survival. #gyncsm http://t.co/6b20oHx8tH
— Lisa M Guzzardi, RN (@LguzzardiM) April 9, 2015
T2: Which ovarian cancer research results are most exciting to you? Immunotherapy? Bevacizumab? Parp inhibitors?
T2: Certainly the PARP inhibitor data are very consistent for #ovariancancer - nice results for #BRCA pts as well as select non-BRCA #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015
T3:
Pls discuss the implications of Dr Joura’s HPV study on cervical cancer
& the Circulating Tumor Cells / Bevacizumab study.
T3: The ability to monitor response to therapy with a blood marker ie "liquid biopsy" is a huge innovation #gyncsm
— Shannon Westin (@ShannonWestin) April 9, 2015
@gyncsm: studies re: BRCA 1) majority of BRCA carriers don’t have family hx 2) most ovarian cancer patients don’t know BRCA status.
T4: How will these BRCA studies impact surveillance, ed, treatment?
#SGO2015 Ian Jacobs. Most BRCA mutation carriers don't have a family hx of cancer pic.twitter.com/M0Sp798Tqw
— Jurgen Piek (@JurgenPiek) March 29, 2015
@btrfly12 most gyn cancer centers auto referring for genetic testing after ovca dx. #gyncsm
— Don S Dizon (@drdonsdizon) April 9, 2015
T5: Now we open the chat for questions from our participants re: news they heard from the SGO mtg.
- T5: any studies reveal benefit regarding endo ca recvng maint chemo Stage IIIc2 currently NED A:Nothing yet - we need more maintenance studies for gynecologic cancers
- T5: Question - any radiation oncology news from SGO? A:there was very little major research on #radonc this year
- T5: Does current genetic testing for #OC include mutations like TP53,RAD51D,etc ? Or just BRCA?Is this imp ? A:#gyncsm panel testing test for many more mutations. should speak w genetic counselor. some is imp, some for future #sgo2015
- T5:Thoughts on how should patients/loved ones approach new study findings? A:Open mindedness and always validate its credibility too
Our next chat will be at 9pm EST on May 13, 2015 . We will be joined by Kelly Mellott (@HelomicsCancer) as we discuss Personalized Medicine Advances for GYN Cancers.
Dee
Co-moderator #gyncsm chat
Resources shared during the chat:
Highlights from the SGO Mtg
http://www.cancernetwork.com/conference-report/top-highlights-2015-sgo-annual-meeting
@SGO_org paper on end-points in Clinical trials
https://t.co/gNiU6SUICP
Incidental power morcellation of malignancy: a retrospective cohort study. - PubMed - NCBI
http://t.co/pJOVG9XCfr
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
http://jama.jamanetwork.com/article.aspx?articleid=2214084#.VSXXv-chiQ8.twitter
Advanced Cervical Cancer and Circulating Tumor Cells treated with Bevacizumab
http://www.targetedonc.com/conference/sgo-2015/Patients-with-Advanced-Cervical-Cancer-and-Circulating-Tumor-Cells-Treated-With-Bevacizumab-Show-Improved-OS
Postmenopausal HRT & use of estradiol plus levonorgestrel IUD is assoc with increased risk of fallopian tube cancer
http://t.co/ppFIu9EDou
Postmenopausal HRT & use of estradiol plus levonorgestrel IUD is assoc with increased risk of fallopian tube cancer
http://t.co/ppFIu9EDou
Additional Resources:
diagnostic tool- bracaAnalysis
Endometrial Cancer -Cediranib
http://www.targetedonc.com/conference/sgo-2015/Cediranib-Monotherapy-Safe-Effective-in-Endometrial-Cancer
SGO Highlights:
Women of Teal Blog:
http://womenofteal.blogspot.com/2015/03/sgo-from-distance.html and http://womenofteal.blogspot.com/2015/03/sgo-from-distance-part-2.html
http://womenofteal.blogspot.com/2015/03/sgo-from-distance.html and http://womenofteal.blogspot.com/2015/03/sgo-from-distance-part-2.html
AVASTIN GOG 213
OncLive “overall survival (OS) of nearly 5 months compared with
chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer,
according to results from the phase III GOG0213: “
mixed results GOG 213 http://www.medpagetoday.com/MeetingCoverage/SGO/50720
Surgeon vs CT results of size of tumors left behind.
Fosbretabulin /Avastin
OXiGENE Announces Presentation of Phase 2
Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly
Increases Progression-Free Survival in Recurrent Ovarian Cancer
Immunotherapy
IP chemo advantages
Recommendations for the prevention of ovarian
cancer : SGO
Dr Brawleys commentary-http://onlinelibrary.wiley.com/enhanced/doi/10.1002/cncr.29347/
PARP inhibitor - olaparib (Lynparza)
diagnostic tool- bracaAnalysis
FANG vaccine trial / Immunotherapy
Endometrial Cancer -Cediranib
http://www.targetedonc.com/conference/sgo-2015/Cediranib-Monotherapy-Safe-Effective-in-Endometrial-Cancer
No comments:
Post a Comment